Li Zhang

ORCID: 0009-0001-3828-8113
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lung Cancer Treatments and Mutations
  • Lung Cancer Diagnosis and Treatment
  • Lung Cancer Research Studies
  • Lymphoma Diagnosis and Treatment
  • Peptidase Inhibition and Analysis
  • Colorectal Cancer Treatments and Studies
  • Cancer Diagnosis and Treatment
  • Cancer Research and Treatments
  • Cancer therapeutics and mechanisms
  • Carbohydrate Chemistry and Synthesis
  • Chemical Reactions and Isotopes
  • Bioactive Compounds and Antitumor Agents
  • Sarcoma Diagnosis and Treatment
  • Cardiac tumors and thrombi
  • Immunodeficiency and Autoimmune Disorders
  • Synthesis and biological activity
  • Synthesis of Indole Derivatives
  • Systemic Sclerosis and Related Diseases
  • Metastasis and carcinoma case studies
  • HER2/EGFR in Cancer Research
  • Ferroptosis and cancer prognosis
  • Gastric Cancer Management and Outcomes
  • Melanoma and MAPK Pathways
  • Inflammatory Myopathies and Dermatomyositis
  • Viral-associated cancers and disorders

Sun Yat-sen University
2016-2024

Sun Yat-sen University Cancer Center
2016-2024

State Key Laboratory of Oncology in South China
2024

Chinese Academy of Medical Sciences & Peking Union Medical College
2024

Huazhong University of Science and Technology
2024

Tongji Hospital
2024

Shanxi Province Hospital of Traditional Chinese Medicine
2023

Abstract Dual inhibition of vascular endothelial growth factor and epidermal receptor (EGFR) signaling pathways offers the prospect improving effectiveness EFGR-targeted therapy. In this phase 3 study (ClinicalTrial.gov: NCT04028778), 315 patients with treatment-naïve, EGFR- mutated, advanced non-small cell lung cancer (NSCLC) were randomized (1:1) to receive anlotinib or placebo plus gefitinib once daily on days 1–14 per a 3-week cycle. At prespecified final analysis progression-free...

10.1038/s41392-024-01927-9 article EN cc-by Signal Transduction and Targeted Therapy 2024-08-13

Pediatric lymphoepithelioma-like carcinoma (pLELC) is a rare neoplasm with unclear prognosis, genome, and tumor microenvironment. Our study aims to elucidate its genomic clinical characteristics. Forty-one pLELC patients were enrolled at Sun Yat-sen University Cancer Center from 2012 2023. Kaplan–Meier analysis was utilized estimate progression-free survival (PFS) overall (OS). Baseline plasma protein levels 16 9 health controls analyzed using Olink proteomic platform whole exon sequence...

10.1186/s12967-024-05921-1 article EN cc-by-nc-nd Journal of Translational Medicine 2024-12-04

Primary pulmonary osteosarcoma is one of the extraskeletal osteosarcomas originating from lung with an extremely low incidence and highly invasive potential. Here we report a case primary treated in our hospital literature review. The patient, 17-year-old male, had cough hemoptysis for 20 days. Computed tomography (CT) positron emission (PET)/CT were performed hospital. According to pathological examination after surgery, tumor was diagnosed as high-grade sarcoma remarkable osteogenesis...

10.3389/fmed.2024.1364937 article EN cc-by Frontiers in Medicine 2024-03-21

Abstract Introduction: Studies have shown that molecular targeted therapy can mediate Gasdermin-E (GSDME) dependent pyroptosis. However, GSDME expression is suppressed in many mutated patients, including those with KRAS-G12C-mutated non-small-cell lung cancer (NSCLC). The efficacy of AMG510 against KRAS-G12C inhibition (KRAS-G12Ci) constrained by tumor recurrence. Pyroptosis widely involved the occurrence and development tumors. role mechanism pyroptosis not been well identified. Here, we...

10.1158/1538-7445.am2024-lb266 article EN Cancer Research 2024-04-05

TPS8665 Background: Tumor Treating Fields (TTFields) are electric fields that disrupt processes critical for cancer cell viability. TTFields delivered by a noninvasive portable device has the European CE Mark and FDA approval glioblastoma mesothelioma. Preclinical non-small lung (NSCLC) studies demonstrated enhance antitumor immune response, through disruption of mitosis subsequent induction immunogenic death. The pivotal, phase III LUNAR study (NCT02973789) in metastatic NSCLC progressing...

10.1200/jco.2024.42.16_suppl.tps8665 article EN Journal of Clinical Oncology 2024-06-01

The decision for definitive therapy the treatment of patients with connective tissue disease-associated interstitial lung disease (CTD-ILD) is difficult. Patients CTD-ILD received 0.5 g twice a day mycophenolate mofetil 2 years (MMF cohort, n = 105) or cyclophosphamide 50 mg once every other day, and cumulative dose should not exceed 10 (CYC 140). After complete (EL), % forced vital capacity (FVC) diffusing lungs carbon monoxide were increased in both MMF CYC cohorts as compared to before (p...

10.1515/med-2023-0838 article EN cc-by Open Medicine 2023-01-01

10.1016/j.jtho.2017.09.181 article EN publisher-specific-oa Journal of Thoracic Oncology 2017-11-01

Introduction: Radiotherapy is extremely important in extranodal natural killer/T-cell lymphoma (ENKTL). [18F]-Fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) a routine pretreatment imaging technique used ENKTL, while magnetic resonance (MRI) plays key role head and neck (HN) cancer. The purpose of this study was to investigate the value HN-MRI PET/CT-guided therapy improving survival upper aerodigestive tract ENKTL (UADT-ENKTL). Methods: We prospectively...

10.1002/hon.85_2630 article EN Hematological Oncology 2019-06-01
Coming Soon ...